A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
1 other identifier
observational
260
1 country
1
Brief Summary
The purpose of this research study is to understand more about various heart rhythms (electrical problems) in persons with hypertrophic cardiomyopathy with and without sleep apnea.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 28, 2019
CompletedFirst Posted
Study publicly available on registry
October 2, 2019
CompletedStudy Start
First participant enrolled
November 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
February 5, 2026
February 1, 2026
8.1 years
September 28, 2019
February 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Atrial fibrillation incidence in hypertrophic cardiomyopathy
Define the incidence ratio of newly diagnosed atrial fibrillation in hypertrophic cardiomyopathy, with and without sleep apnea
Final incidence to be calculated at study conclusion, after 3 years of rhythm monitoring.
Atrial fibrillation recurrence in hypertrophic cardiomyopathy
Determine the frequency of recurrent atrial fibrillation in hypertrophic cardiomyopathy, with and without sleep apnea
Final recurrence rate to be calculated at study conclusion, after 3 years of rhythm monitoring.
Ventricular arrhythmia incidence in hypertrophic cardiomyopathy
Define the incidence ratio of newly diagnosed ventricular arrhythmias in hypertrophic cardiomyopathy, with and without sleep apnea
Final incidence to be calculated at study conclusion, after 3 years of rhythm monitoring.
Eligibility Criteria
Adult patients with hypertrophic cardiomyopathy who are participating in (or previously participated in) Mayo Clinic study 17-003514 and/or 16-009474
You may qualify if:
- Currently or previously enrolled in 17-003514 and 16-009474
- Adults age \>18 years-old with a diagnosis of hypertrophic cardiomyopathy
- Both sexes
- Able to consent
You may not qualify if:
- Vulnerable study population
- Known atrial fibrillation or flutter (with the exception of post-operative atrial fibrillation)
- Pacemaker/ICD implantation
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- Medtroniccollaborator
Study Sites (1)
Mayo Clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jeffrey Geske, MD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 28, 2019
First Posted
October 2, 2019
Study Start
November 5, 2019
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
February 5, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share